TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Psyence Biomedical ( (PBM) ) just unveiled an announcement.
On August 15, 2025, Psyence Biomedical Ltd. entered into a subscription agreement with Psyence Labs Ltd., acquiring 1,750 shares at $2,000 each, totaling $3,500,000. The transaction, which closed on September 1, 2025, strengthens Psyence Biomedical’s investment in Psyence Labs, a company specializing in psychedelic pharmaceutical ingredients. This move may enhance Psyence Biomedical’s market position in the psychedelic pharmaceutical industry, potentially benefiting stakeholders through expanded research and development capabilities.
More about Psyence Biomedical
Psyence Biomedical Ltd. operates in the pharmaceutical industry, focusing on the development and production of psychedelic active pharmaceutical ingredients and extracts for research, clinical trials, and drug development. The company is involved in psychedelic cultivation and extraction, exporting raw materials and extracts to research partners, and developing proprietary extraction methodologies.
Average Trading Volume: 1,662,230
Technical Sentiment Signal: Sell
Current Market Cap: $1.84M
Find detailed analytics on PBM stock on TipRanks’ Stock Analysis page.